Welcome Stockaholics!

We are a new and fast growing financial forum! Sign up for free and let's talk stocks!

  1. Do you want to help develop this community? We are looking for contributions from investors and traders like you! What stocks do you follow? What is hot right now? Sign up and get in on the ground floor of the newest, fastest growing financial forum!
    Dismiss Notice
  2. You will notice a live chat widget on the right. Click in to join us and lets hear about how you nailed that last UWTI trade!
    Dismiss Notice

EVFM - Evofem Biosciences

Discussion in 'Stock Message Boards NYSE, NASDAQ, AMEX' started by Dan Thunderbolt, Sep 12, 2020.

  1. Dan Thunderbolt

    Dan Thunderbolt Active Member

    Joined:
    Aug 26, 2017
    Messages:
    679
    Likes Received:
    73
    The share price of this company has plummeted to an alltime low. Nevertheless the company seems to have a great beneficial FDA approved product called Phexxi which has huge potential and is currently being launched. The reason for the share price drop on Friday was probably that the CEO has sold some shares. Reading some forums it appears the reasons of her selling some of her shares are of private nature and are quite reasonable.

    I have not bought any shares yet, but will consider if I free up funds elsewhere...

    Information on the potential of Phexxi
    https://www.nasdaq.com/articles/3-top-biotech-stocks-with-fda-approvals-on-the-horizon-2020-04-19

    EVFM earnings call for the period ending June 30, 2020.
    https://evofem.investorroom.com/download/2020.08.04_EVFM+Q2+2020+Transcript_FINAL.pdf

    Evofem Announces Pricing of Approximately $100 Million Public Offering of Common Stock
    https://evofem.investorroom.com/202...y-100-Million-Public-Offering-of-Common-Stock

    [​IMG]
     
    T0rm3nted likes this.
  2. Dan Thunderbolt

    Dan Thunderbolt Active Member

    Joined:
    Aug 26, 2017
    Messages:
    679
    Likes Received:
    73
    This one is doing pretty well recently. I listened to one of their recent webcasts. If the roll-out of their product launch is succesful this will make nice returns.
     
  3. Dan Thunderbolt

    Dan Thunderbolt Active Member

    Joined:
    Aug 26, 2017
    Messages:
    679
    Likes Received:
    73
    Finally bought a first position in the past couple of days. I am very confident that EVFM has a high chance of a nice return on investment 12 months down the road ($8-$10). If Phexxi is a success the market cap is way too low.

    Current price is $2.35

    Below are some interesting items from the recent Q3 Conference Call November 9:

    https://seekingalpha.com/article/43...r-on-q3-2020-results-earnings-call-transcript
    • In the second half of 2020 Evofem has achieved three significant milestones. In September, we launched Phexxi, the first and only non-hormonal prescription contraceptive drugs for on-demand use. In October we closed the $25 million strategic investment from Adjuvant Capital. And we initiated our pivotal Phase III trial of EVO100 for the prevention of chlamydia and the prevention of gonorrhea in women (Adjuvant Capital invested because of this product).
    • On September 8, we announced the commercial launch of Phexxi despite the challenges, we faced launching a commercial product in the midst of COVID-19, we are proud of our early momentum and we're confident about the long-term success of Phexxi, considering that there are 21 million women in the United States who are beyond hormones. Phexxi has conservatively a billion-dollar market opportunity, in fact, so listen to this part. If we can just acquire 3% of these 21 million women that's just 630,000 women out of the 21 million that are already beyond hormones and they fill their prescriptions seven times in one year, we will achieve this potential. Once again, this illustrates that small percentages of market share will deliver very big results for Phexxi.
    • For well over a year, we built a strong relationship with Adjuvant Capital, they are backed by the Bill and Melinda Gates Foundation and other global public health leaders like Merck and Novartis. Adjuvant is deeply aligned with our core mission, developing and commercializing innovative products to address critical sexual and reproductive health concerns of women. There are $25 million investment without a premium to the market on the date of close, as well as the premium to the fundraising round we completed in June. This is Adjuvant’s largest single investment to-date. What is important is that what that testifies to is the confidence that they have in this team and the importance of introducing true innovation in women's health, not just me too products in crowded categories.
    • Phexxi is off to a strong start. Right out of the gate healthcare providers started writing Phexxi prescriptions. In third quarter, which includes only the first three weeks of data, Phexxi was able to achieve 385 prescriptions, and we had our first refill before the quarter closed. I look forward to sharing more robust data on our Q4 earnings call in March when we'll have a full quarter plus of data to share and to give us a better idea of the launch trajectory.
    • I want to conclude with a look at the market opportunity for Phexxi. Among the millions of women in the United States who are at risk for pregnancy, and importantly, unintended pregnancy, there are three distinct segments we will target for Phexxi. Our primary segments are first, women using no contraception at all. And also these women who are using non-prescription contraception such as barrier methods, withdraw or periodic abstinence. Our second segment, or as some might say, later adopters are women who are currently using prescription contraception, but who may already be considering moving to a hormone free on-demand method. Phexxi's peak revenue potential is 1.4 to 2.3 billion by achieving only single-digit acquisition percentages of women in each of these three segments.
    • Based on our early indicators of a positive trend and our planned DTC campaign, which will be launched at the end of January, we are confident we can achieve Phexxi's full potential.
    • We closed the quarter with 86.7 million in unrestricted cash and as Saundra mentioned in October, we raised 25 million from Adjuvant Capital. This provides us with runway into the second half of 2021 based on current expense forecasts in cash firm and I want to highlight Phexxi revenue provides upside to this forecast.
     
  4. Dan Thunderbolt

    Dan Thunderbolt Active Member

    Joined:
    Aug 26, 2017
    Messages:
    679
    Likes Received:
    73
  5. Dan Thunderbolt

    Dan Thunderbolt Active Member

    Joined:
    Aug 26, 2017
    Messages:
    679
    Likes Received:
    73
    According to the CEO the big ad campaign for Phexxi will start on valentines day (14 February 2021).

    "It is going to get everybodies attention"

    https://evofem.investorroom.com/events
    EVFM Presentation at H.C. Wainwright BIOCONNECT 2021 Virtual Conference
    Monday, January 11, 2021
     

Share This Page